NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?

E-ISSN： 1873-4294|7|17|1734-1742

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.7, Iss.17, 2007-09, pp. : 1734-1742

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 17, 2007-01 ,pp. : 1721-1733

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 11, 2014-10 ,pp. : 896-919

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

By Parker E. Van Heek M. Stamford A.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 173-187

Elsevier

Access to resources Recommend Favorite

Novel anti-obesity drugs

By Proietto J. Fam B.C. Ainslie D.A. Thorburn A.W.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1317-1326

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Y-induced contraction is mediated by neuropeptide Y Y 2 and Y 4 receptors in the rat colon

By Pheng L.-H. Perron A. Quirion R. Cadieux A. Fauchere J.L. Dumont Y. Regoli D.

European Journal of Pharmacology, Vol. 374, Iss. 1, 1999-06 ,pp. : 85-91

Elsevier

Access to resources Recommend Favorite